
InnoCan Pharma Corporation
InnoCan Pharma Corporation (INNO.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
inno.cn · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
InnoCan Pharma CorporationYou INNO.CN | $15M | N/A | — | — |
BioNxt Solutions Inc. BNXT.CN | $53M | N/A | — | -$0.06 |
C21 Investments Inc. CXXI.CN | $48M | N/A | — | -$0.03 |
Decibel Cannabis Company Inc. DB.V | $66M | N/A | — | -$0.01 |
iAnthus Capital Holdings, Inc. IAN.CN | $35M | N/A | — | -$0.01 |
Leef Brands Inc. LEEF.CN | $45M | N/A | — | -$0.15 |
Medexus Pharmaceuticals Inc. MDP.TO | $128M | 27.81x | — | $0.09 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for InnoCan Pharma Corporation (INNO.CN) measures how much investors pay for each dollar of the company's trailing earnings. INNO.CN's current PE ratio of N/A is calculated by dividing its stock price of $3.40 by its TTM earnings per share of —.
Frequently asked questions
INNO.CN pe ratio · 6 questionsINNO.CN's current PE ratio is N/A as of 2026-06-10, based on a stock price of $3.40 and TTM EPS of —. Data sourced from Financial Modeling Prep via INNO.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · InnoCan Pharma Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10